ReviewDiabetology international2027
GLP-1 based therapy of obesity and type 2 diabetes.
Review in Diabetology international, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GLP-1 is 30-amino acid peptide that is secreted from the intestine in response to food intake. The release mechanism involves luminal exposure to as well as absorption and metabolism of the major nutrients. It functions mainly as a part of the ileal brake mechanism whereby nutrient entry in distal segments of the small intestine inhibit gastrointestinal secretion and motility as well as appetite and food intake, signalling nutritional abundance. It also functions as a second line incretin hormone. It acts on the brain via sensory vagal afferents, but also interacts with exposed neurons expressing the GLP-1 receptor in the circumventricular organs, in turn activating brain nuclei involved in appetite regulation and reward. High doses of GLP-1 cause nausea and vomiting, but slow dosing titration mitigates this. GLP-1 Receptor Agonists owe their actions to these physiological mechanisms and therefore represent powerful antidiabetic agents (A1c levels below 5.7%) and cause major weight loss (up to 20%), but also appear to reduce the systemic low-grade inflammation of obesity and type 2 diabetes and to exert beneficial action on the blood vessels, providing the GLP-1RAs with preventive effects on cardiovascular, hepatic, renal and central nervous system complications. Orally active GLP-1rAs have also been developed. It is emphasized that GLP-1RA therapy should be accompanied by lifestyle changes for efficacy and to prevent side effects of the weight loss. In addition, any prescription of a GLP-1RA should include a plan to mitigate adverse effects of treatment termination. Nevertheless, GLP-1RAs represent a major breakthrough in the therapy of metabolic disease and are now included among the essential medicines of the WHO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.